Paul S Aisen

Summary

Affiliation: Georgetown University
Country: USA

Publications

  1. ncbi request reprint Induction of the complement component C1qB in brain of transgenic mice with neuronal overexpression of human cyclooxygenase-2
    Lauren Spielman
    Neuroinflammation Research Laboratories, Department of Psychiatry, Box 1229, Mount Sinai School of Medicine, 1 Gustave L Levy Place, New York, NY 10029, USA
    Acta Neuropathol 103:157-62. 2002
  2. ncbi request reprint The potential of anti-inflammatory drugs for the treatment of Alzheimer's disease
    Paul S Aisen
    Department of Neurology, Georgetown University Medical Center, Washington DC 20007, USA
    Lancet Neurol 1:279-84. 2002
  3. ncbi request reprint Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial
    Paul S Aisen
    Department of Neurology, Georgetown University Medical Center, Washington, DC 20057, USA
    JAMA 289:2819-26. 2003
  4. ncbi request reprint The development of anti-amyloid therapy for Alzheimer's disease : from secretase modulators to polymerisation inhibitors
    Paul S Aisen
    Department of Neurology, Georgetown University Medical Center, Washington DC, USA
    CNS Drugs 19:989-96. 2005
  5. ncbi request reprint Steroid-induced elevation of glucose in Alzheimer's disease: relationship to gender, apolipoprotein E genotype and cognition
    P S Aisen
    Department of Neurology, Georgetown University Medical Center, 1Bles Building, 3800 Reservoir Road NW, Washington, DC 20007, USA
    Psychoneuroendocrinology 28:113-20. 2003
  6. ncbi request reprint Anti-inflammatory agents in Alzheimer's disease
    Paul S Aisen
    Department of Neurology, Georgetown University Medical Center, 3800 Reservoir Road NW, 1 Bles Building, Washington, DC 20057, USA
    Curr Neurol Neurosci Rep 2:405-9. 2002
  7. doi request reprint Leon Thal and the therapeutic age of Alzheimer's disease
    Paul S Aisen
    University of California San Diego, San Diego, CA, USA
    Alzheimers Dement 4:S4-6. 2008
  8. ncbi request reprint Randomized pilot study of nimesulide treatment in Alzheimer's disease
    P S Aisen
    Department of Neurology, Georgetown University Medical Center, Washington, DC 20007, USA
    Neurology 58:1050-4. 2002
  9. ncbi request reprint Alzhemed: a potential treatment for Alzheimer's disease
    Paul S Aisen
    Department of Neurology, Georgetown University, Washington, DC 20057, USA
    Curr Alzheimer Res 4:473-8. 2007
  10. pmc Age and apolipoprotein E genotype influence rate of cognitive decline in nondemented elderly
    David P Salmon
    Department of Neurosciences, University of California, San Diego, La Jolla, CA 92093 0948, USA
    Neuropsychology 27:391-401. 2013

Detail Information

Publications84

  1. ncbi request reprint Induction of the complement component C1qB in brain of transgenic mice with neuronal overexpression of human cyclooxygenase-2
    Lauren Spielman
    Neuroinflammation Research Laboratories, Department of Psychiatry, Box 1229, Mount Sinai School of Medicine, 1 Gustave L Levy Place, New York, NY 10029, USA
    Acta Neuropathol 103:157-62. 2002
    ..Because there is extensive evidence that C1q and other complement components are involved in Alzheimer's disease (AD) neurodegeneration, this study advances our understanding of the apparent benefits of COX-2 inhibition in AD...
  2. ncbi request reprint The potential of anti-inflammatory drugs for the treatment of Alzheimer's disease
    Paul S Aisen
    Department of Neurology, Georgetown University Medical Center, Washington DC 20007, USA
    Lancet Neurol 1:279-84. 2002
    ..Several studies, including a large primary prevention trial with NSAIDs, are still in progress. Major issues of selection of patients, drug regimen, and duration of treatment remain unresolved...
  3. ncbi request reprint Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial
    Paul S Aisen
    Department of Neurology, Georgetown University Medical Center, Washington, DC 20057, USA
    JAMA 289:2819-26. 2003
    ....
  4. ncbi request reprint The development of anti-amyloid therapy for Alzheimer's disease : from secretase modulators to polymerisation inhibitors
    Paul S Aisen
    Department of Neurology, Georgetown University Medical Center, Washington DC, USA
    CNS Drugs 19:989-96. 2005
    ..Thus, it is plausible that an effective anti-amyloid strategy will become available for the treatment of Alzheimer's disease within the next few years...
  5. ncbi request reprint Steroid-induced elevation of glucose in Alzheimer's disease: relationship to gender, apolipoprotein E genotype and cognition
    P S Aisen
    Department of Neurology, Georgetown University Medical Center, 1Bles Building, 3800 Reservoir Road NW, Washington, DC 20007, USA
    Psychoneuroendocrinology 28:113-20. 2003
    ..These results support a relationship between gender, apolipoprotein E genotype and glucose metabolism, but do not indicate that mild changes in glucose have an important impact on cognitive function...
  6. ncbi request reprint Anti-inflammatory agents in Alzheimer's disease
    Paul S Aisen
    Department of Neurology, Georgetown University Medical Center, 3800 Reservoir Road NW, 1 Bles Building, Washington, DC 20057, USA
    Curr Neurol Neurosci Rep 2:405-9. 2002
    ....
  7. doi request reprint Leon Thal and the therapeutic age of Alzheimer's disease
    Paul S Aisen
    University of California San Diego, San Diego, CA, USA
    Alzheimers Dement 4:S4-6. 2008
  8. ncbi request reprint Randomized pilot study of nimesulide treatment in Alzheimer's disease
    P S Aisen
    Department of Neurology, Georgetown University Medical Center, Washington, DC 20007, USA
    Neurology 58:1050-4. 2002
    ..Clinical and laboratory experience with nimesulide, an NSAID with preferential cyclooxygenase-2 inhibition, suggests that it may be a good candidate for AD therapy...
  9. ncbi request reprint Alzhemed: a potential treatment for Alzheimer's disease
    Paul S Aisen
    Department of Neurology, Georgetown University, Washington, DC 20057, USA
    Curr Alzheimer Res 4:473-8. 2007
    ..These findings will be discussed in the context of two large-scale randomized, double-blind, placebo-controlled Phase III clinical trials that are currently being conducted to test the long-term safety and efficacy of Alzhemed...
  10. pmc Age and apolipoprotein E genotype influence rate of cognitive decline in nondemented elderly
    David P Salmon
    Department of Neurosciences, University of California, San Diego, La Jolla, CA 92093 0948, USA
    Neuropsychology 27:391-401. 2013
    ....
  11. doi request reprint Levels of soluble and insoluble tau reflect overall status of tau phosphorylation in vivo
    Chiho Hirata-Fukae
    Department of Neurology, Georgetown University Medical Center, Washington, DC 20057, USA
    Neurosci Lett 450:51-5. 2009
    ..Taken together, these findings suggest that levels of soluble and insoluble tau are indicative of overall levels of tau phosphorylation, and may be useful markers to evaluate the effects of anti-tau therapeutic strategies in vivo...
  12. pmc Ventricular enlargement and its clinical correlates in the imaging cohort from the ADCS MCI donepezil/vitamin E study
    Liana G Apostolova
    Department of Neurology, University of California Los Angeles, Los Angeles, CA 90095, USA
    Alzheimer Dis Assoc Disord 27:174-81. 2013
    ..After correction for baseline hippocampal volume, decline in ADL showed a significant association with right frontal horn enlargement. Executive decline was associated with right frontal and left temporal horn enlargement...
  13. pmc Symptomatic and nonamyloid/tau based pharmacologic treatment for Alzheimer disease
    Paul S Aisen
    University of California, San Diego, California 92093, USA
    Cold Spring Harb Perspect Med 2:a006395. 2012
    ..We also review putative therapies that aim to slow disease progression by mechanisms not directly related to amyloid or tau...
  14. pmc Amyloid-β--associated clinical decline occurs only in the presence of elevated P-tau
    Rahul S Desikan
    Department of Radiology, University of California San Diego, 8950 Villa La Jolla Dr, Ste C101, La Jolla, CA 92037 0841, USA
    Arch Neurol 69:709-13. 2012
    ..To elucidate the relationship between the 2 hallmark proteins of Alzheimer disease (AD), amyloid-(Aβ) and tau, and clinical decline over time among cognitively normal older individuals...
  15. pmc Influence of apolipoprotein E varepsilon4 on rates of cognitive and functional decline in mild cognitive impairment
    Danielle C Whitehair
    Department of Neurosciences, University of California, San Diego, CA, USA
    Alzheimers Dement 6:412-9. 2010
    ..We examine the prospective association of APOE varepsilon4 allele status on measures of cognitive and functional decline in subjects with amnestic MCI (aMCI)...
  16. pmc High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: a randomized controlled trial
    Paul S Aisen
    Department of Neurosciences, University of California, San Diego, 9500 Gilman Dr, M C 0949, La Jolla, CA 92093, USA
    JAMA 300:1774-83. 2008
    ..Prior studies of B vitamins to reduce homocysteine in AD have not had sufficient size or duration to assess their effect on cognitive decline...
  17. pmc Amyloid-β associated volume loss occurs only in the presence of phospho-tau
    Rahul S Desikan
    Department of Radiology, University of California San Diego, La Jolla 92037, CA
    Ann Neurol 70:657-61. 2011
    ..Our findings indicate that Aβ-associated volume loss occurs only in the presence of phospho-tau in humans at risk for dementia...
  18. pmc 3D PIB and CSF biomarker associations with hippocampal atrophy in ADNI subjects
    Liana G Apostolova
    Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA, United States
    Neurobiol Aging 31:1284-303. 2010
    ..p-tau(181) showed stronger correlation in ApoE4 carriers, while t-tau showed stronger correlation in ApoE4 noncarriers. Of the 3 PIB measures the precuneal SUVR showed strongest associations with hippocampal atrophy...
  19. ncbi request reprint The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception
    Michael W Weiner
    Department of Veterans Affairs Medical Center, Center for Imaging of Neurodegenerative Diseases, San Francisco, CA, USA
    Alzheimers Dement 9:e111-94. 2013
    ..The ADNI study was extended by a 2-year Grand Opportunities grant in 2009 and a renewal of ADNI (ADNI-2) in October 2010 through to 2016, with enrollment of an additional 550 participants. ..
  20. ncbi request reprint Females exhibit more extensive amyloid, but not tau, pathology in an Alzheimer transgenic model
    Chiho Hirata-Fukae
    Department of Neurology, Georgetown University Medical Center, Washington, DC 20057, USA
    Brain Res 1216:92-103. 2008
    ..These findings confirm progressive Abeta pathology in 3xTg-AD transgenic mice, and provide guidance for their use in therapeutic research...
  21. ncbi request reprint A phase 3 trial of semagacestat for treatment of Alzheimer's disease
    Rachelle S Doody
    Alzheimer s Disease and Memory Disorders Center, Department of Neurology, Baylor College of Medicine, Houston, TX 77030, USA
    N Engl J Med 369:341-50. 2013
    ..Semagacestat is a small-molecule γ-secretase inhibitor that was developed as a potential treatment for Alzheimer's disease...
  22. pmc Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial
    Joseph F Quinn
    Department of Neurology, Oregon Health and Science University, Portland, OR 97239, USA
    JAMA 304:1903-11. 2010
    ..Epidemiological studies suggest that consumption of DHA is associated with a reduced incidence of Alzheimer disease. Animal studies demonstrate that oral intake of DHA reduces Alzheimer-like brain pathology...
  23. pmc 3D comparison of low, intermediate, and advanced hippocampal atrophy in MCI
    Liana G Apostolova
    Department of Neurology, David Geffen School of Medicine, UCLA, CA, USA
    Hum Brain Mapp 31:786-97. 2010
    ..Greater CA1 and subicular atrophy can be demonstrated early and is predictive of future conversion to AD, whereas CA2-3 involvement becomes more evident as the disease progresses...
  24. ncbi request reprint Rofecoxib in patients with mild cognitive impairment: further analyses of data from a randomized, double-blind, trial
    Paul S Aisen
    Georgetown University Medical Center, Washington, DC, USA
    Curr Alzheimer Res 5:73-82. 2008
    ..The significance of the observation that rofecoxib increased the rate of conversion from MCI to AD remains uncertain...
  25. pmc The Alzheimer's disease neuroimaging initiative: progress report and future plans
    Michael W Weiner
    Center for Imaging of Neurodegenerative Diseases, San Francisco VA Medical Center, San Francisco, CA, USA
    Alzheimers Dement 6:202-11.e7. 2010
    ..All data are available at UCLA/LONI/ADNI, without embargo. ADNI-like projects started in Australia, Europe, Japan, and Korea. ADNI provides significant new information concerning the progression of AD...
  26. pmc Apolipoprotein E (APOE) genotype has dissociable effects on memory and attentional-executive network function in Alzheimer's disease
    David A Wolk
    Department of Neurology, University of Pennsylvania, Philadelphia, PA 19104, USA
    Proc Natl Acad Sci U S A 107:10256-61. 2010
    ....
  27. pmc Clinical and biomarker changes in dominantly inherited Alzheimer's disease
    Randall J Bateman
    Washington University School of Medicine, Department of Neurology, 660 S Euclid Ave, Box 8111, St Louis, MO 63110, USA
    N Engl J Med 367:795-804. 2012
    ..Autosomal dominant Alzheimer's disease has a predictable age at onset and provides an opportunity to determine the sequence and magnitude of pathologic changes that culminate in symptomatic disease...
  28. pmc The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception
    Michael W Weiner
    Department of Veterans Affairs Medical Center, Center for Imaging of Neurodegenerative Diseases, San Francisco, CA, USA
    Alzheimers Dement 8:S1-68. 2012
    ..The ADNI study was extended by a 2-year Grand Opportunities grant in 2009 and a renewal of ADNI (ADNI-2) in October 2010 through to 2016, with enrollment of an additional 550 participants...
  29. doi request reprint A neuronal microtubule-interacting agent, NAPVSIPQ, reduces tau pathology and enhances cognitive function in a mouse model of Alzheimer's disease
    Yasuji Matsuoka
    Department of Neurology, Georgetown University Medical Center, 4000 Reservoir Road N W, Washington, DC 20057, USA
    J Pharmacol Exp Ther 325:146-53. 2008
    ..Our results suggest that neuronal microtubule interacting agents such as NAP may be useful therapeutic agents for the treatment or prevention of tauopathies...
  30. pmc Agreement in cognitive and clinical assessments in Alzheimer's disease
    Rochelle E Tractenberg
    Departments of Neurology, Biostatistics, Bioinformatics and Biomathematics, and Psychiatry, Georgetown University School of Medicine, Washington, D C 20057, USA
    Dement Geriatr Cogn Disord 27:344-52. 2009
    ..To estimate agreement among scores on three common assessments of cognitive function...
  31. doi request reprint Safety and biomarker effects of solanezumab in patients with Alzheimer's disease
    Martin Farlow
    Department of Neurology, Indiana University School of Medicine, Indianapolis, USA
    Alzheimers Dement 8:261-71. 2012
    ..Cognitive measures were also obtained...
  32. ncbi request reprint ADCS Prevention Instrument Project: the Mail-In Cognitive Function Screening Instrument (MCFSI)
    Sally P Walsh
    Department of Neurology, Georgetown University Medical Center, Washington, DC 20057, USA
    Alzheimer Dis Assoc Disord 20:S170-8. 2006
    ....
  33. pmc Beta-site amyloid precursor protein-cleaving enzyme-1 (BACE1)-mediated changes of endogenous amyloid beta in wild-type and transgenic mice in vivo
    Chiho Hirata-Fukae
    Department of Neurology, Georgetown University Medical Center, Washington, DC 20057, USA
    Neurosci Lett 435:186-9. 2008
    ..Further, these results suggest that substantial inhibition of BACE1 in brain may be required for clinical benefit in Alzheimer's disease...
  34. pmc Clinical Core of the Alzheimer's Disease Neuroimaging Initiative: progress and plans
    Paul S Aisen
    Department of Neurosciences, University of California San Diego, CA, USA
    Alzheimers Dement 6:239-46. 2010
    ..The resulting data would provide valuable data on the earliest stages of AD, and support the development of interventions in these critically important populations...
  35. pmc Neuroimaging enrichment strategy for secondary prevention trials in Alzheimer disease
    Linda K McEvoy
    Department of Radiology, University of California, San Diego, La Jolla, CA 92093 0841, USA
    Alzheimer Dis Assoc Disord 24:269-77. 2010
    ..Failure to take into account normal age-related changes risks under-powering trials designed to test disease-modifying properties of potential treatments...
  36. pmc NIA-funded Alzheimer centers are more efficient than commercial clinical recruitment sites for conducting secondary prevention trials of dementia
    Steven D Edland
    Department of Neurosciences, University of California San Diego, La Jolla, CA, USA
    Alzheimer Dis Assoc Disord 24:159-64. 2010
    ..Targeted retention efforts and utilization of academic sites could substantively improve the statistical power and validity of future clinical trials of cognitively impaired elderly...
  37. ncbi request reprint The preclinical Alzheimer cognitive composite: measuring amyloid-related decline
    Michael C Donohue
    Division of Biostatistics and Bioinformatics, Department of Family and Preventive Medicine, University of California, San Diego, La Jolla2Alzheimer s Disease Cooperative Study, Department of Neurosciences, University of California, San Diego, La Jolla
    JAMA Neurol 71:961-70. 2014
    ..As Alzheimer disease (AD) research moves to intervene in presymptomatic phases of the disease, we must develop outcome measures sensitive to the earliest disease-related changes...
  38. pmc Longitudinal stability of subsyndromal symptoms of depression in individuals with mild cognitive impairment: relationship to conversion to dementia after 3 years
    R Scott Mackin
    Department of Psychiatry, University of California, San Francisco, CA, USA
    Int J Geriatr Psychiatry 27:355-63. 2012
    ..To evaluate the degree to which longitudinal stability of subsyndromal symptoms of depression (SSD) is associated with conversion to dementia in patients with mild cognitive impairment (MCI)...
  39. pmc Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
    Reisa A Sperling
    Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
    Alzheimers Dement 7:280-92. 2011
    ....
  40. ncbi request reprint Applications of neuroimaging to disease-modification trials in Alzheimer's disease
    Adam S Fleisher
    Department of Neurosciences, University of California, San Diego, USA
    Behav Neurol 21:129-36. 2009
    ..This review discusses recently presented data from the ADNI dataset, and the importance of imaging in the future of drug development in AD...
  41. pmc MRI substudy participation in Alzheimer disease (AD) clinical trials: baseline comparability of a substudy sample to entire study population
    Rema Raman
    Department of Neurosciences, University of California San Diego, La Jolla, 92093 0717, USA
    Alzheimer Dis Assoc Disord 23:333-6. 2009
    ..To determine if a self-selected group of participants who enroll in an imaging substudy of Alzheimer disease (AD) clinical trials is representative of the overall study sample...
  42. ncbi request reprint Intranasal NAP administration reduces accumulation of amyloid peptide and tau hyperphosphorylation in a transgenic mouse model of Alzheimer's disease at early pathological stage
    Yasuji Matsuoka
    Department of Neurology, Georgetown University Medical Center, Washington, DC 20057, USA
    J Mol Neurosci 31:165-70. 2007
    ..Our results indicate that NAP treatment of transgenic mice initiated at an early stage reduced both Abeta and tau pathology, suggesting that NAP might be a potential therapeutic agent for AD...
  43. ncbi request reprint Neuropsychiatric symptoms and regional neocortical atrophy in mild cognitive impairment and Alzheimer's disease
    Michael S Rafii
    1Department of Neurosciences, University of California, San Diego, CA, USA
    Am J Alzheimers Dis Other Demen 29:159-65. 2014
    ..To assess the relationship between regional neocortical atrophy and psychotic symptoms in adults with mild cognitive impairment (MCI) and Alzheimer's disease (AD)...
  44. ncbi request reprint Effects of traumatic brain injury and posttraumatic stress disorder on Alzheimer's disease in veterans, using the Alzheimer's Disease Neuroimaging Initiative
    Michael W Weiner
    Department of Veterans Affairs Medical Center, Center for Imaging of Neurodegenerative Diseases, San Francisco, CA, USA Department of Radiology, University of California, San Francisco, CA, USA Department of Medicine, University of California, San Francisco, CA, USA Department of Psychiatry, University of California, San Francisco, CA, USA Department of Neurology, University of California, San Francisco, CA, USA Electronic address
    Alzheimers Dement 10:S226-35. 2014
    ..This study is a first step toward the design and statistical powering of an AD prevention trial using at-risk veterans as subjects, and provides the basis for a larger, more comprehensive study of dementia risk factors in veterans. ..
  45. pmc Nonlinear time course of brain volume loss in cognitively normal and impaired elders
    Norbert Schuff
    Center for Imaging of Neurodegenerative Diseases and VA Medical Center, San Francisco, CA, USA
    Neurobiol Aging 33:845-55. 2012
    ..The approach has potential uses for early detection of AD and differentiation between stable and progressing MCI...
  46. pmc The relationship of plasma Abeta levels to dementia in aging individuals with Down syndrome
    Yasuji Matsuoka
    Department of Neurology, Georgetown University Medical Center, Washington, DC, USA
    Alzheimer Dis Assoc Disord 23:315-8. 2009
    ....
  47. pmc Plasma urate and progression of mild cognitive impairment
    Michael C Irizarry
    Department of Neurology, Massachusetts General Hospital, Boston, MA, USA
    Neurodegener Dis 6:23-8. 2009
    ..Impaired antioxidant defenses are implicated in neurodegenerative disease. The plasma levels of urate, a water-soluble antioxidant, are reduced in Alzheimer's disease (AD)...
  48. ncbi request reprint Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials
    Michael Grundman
    Alzheimer s Disease Cooperative Study, Department of Neurosciences, University of California San Diego, 8950 Villa La Jolla Drive, Suite 227, La Jolla, CA 92037, USA
    Arch Neurol 61:59-66. 2004
    ..The Memory Impairment Study (MIS) is a multicenter clinical trial in patients with MCI designed to evaluate whether vitamin E or donepezil is effective at delaying the time to a clinical diagnosis of AD...
  49. pmc Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease
    Adam S Fleisher
    University of California, San Diego, La Jolla, CA 92037, USA
    Arch Neurol 65:1031-8. 2008
    ..To evaluate the safety, tolerability, and amyloid beta (Abeta) response to the gamma-secretase inhibitor LY450139 in Alzheimer disease...
  50. ncbi request reprint One-trial 10-item free-recall performance in Taiwanese elderly and near-elderly: A potential screen for cognitive decline
    Rochelle E Tractenberg
    Department of Biomathematics and Biostatistics, Georgetown University School of Medicine, Washington, DC, USA
    Am J Alzheimers Dis Other Demen 20:239-47. 2005
    ....
  51. ncbi request reprint A pilot study of vitamins to lower plasma homocysteine levels in Alzheimer disease
    Paul S Aisen
    Department of Neurology, Georgetown University Medical Center, Washington, DC 20007, USA
    Am J Geriatr Psychiatry 11:246-9. 2003
    ..Authors determined the impact of high-dose vitamin supplements on plasma homocysteine levels in patients with Alzheimer disease (AD)...
  52. pmc Using the Guttman scale to define and estimate measurement error in items over time: the case of cognitive decline and the meaning of "points lost"
    Rochelle E Tractenberg
    Department of Neurology, Georgetown University Medical Center, Washington, District of Columbia, United States of America
    PLoS ONE 7:e30019. 2012
    ..We found that measurement error, as we defined it, was inconsistent over time and across cognitive functioning levels, violating the theory underlying reliability and other psychometric characteristics, and key regression assumptions...
  53. pmc Clinical trial methodologies for disease-modifying therapeutic approaches
    Paul S Aisen
    Department of Neurosciences, University of California San Diego, La Jolla, CA 92093, USA
    Neurobiol Aging 32:S64-6. 2011
    ..Data suggest that neuroimaging biomarkers will be useful as endpoints for trials in very early, even asymptomatic disease, though further work is necessary to establish validity for regulatory purposes...
  54. pmc Tramiprosate in mild-to-moderate Alzheimer's disease - a randomized, double-blind, placebo-controlled, multi-centre study (the Alphase Study)
    Paul S Aisen
    University of California, San Diego, La Jolla, CA, USA
    Arch Med Sci 7:102-11. 2011
    ..The aim of the study was to assess the clinical efficacy, safety, and disease-modification effects of tramiprosate (homotaurine, ALZHEMED(TM)) in mild-to-moderate Alzheimer's disease (AD)...
  55. pmc A commonly carried allele of the obesity-related FTO gene is associated with reduced brain volume in the healthy elderly
    April J Ho
    Laboratory of Neuroimaging, Department of Neurology, University of California School of Medicine, Los Angeles, CA 90095, USA
    Proc Natl Acad Sci U S A 107:8404-9. 2010
    ..These brain maps reveal that a commonly carried susceptibility allele for obesity is associated with structural brain atrophy, with implications for the health of the elderly...
  56. ncbi request reprint Evaluation of selective COX-2 inhibitors for the treatment of Alzheimer's disease
    Paul S Aisen
    Departments of Neurology and Medicine, Georgetown University Medical Center, Washington, DC 20007, USA
    J Pain Symptom Manage 23:S35-40. 2002
    ..This study, along with other clinical studies currently under way, will determine the utility of selective and nonselective COX inhibitors for the prevention and treatment of AD...
  57. ncbi request reprint Antibody against C-terminal Abeta selectively elevates plasma Abeta
    Audrey J Gray
    Department of Neurology, Georgetown University Medical Center, Washington, DC 20057, USA
    Neuroreport 18:293-6. 2007
    ..In this study, we found that anti-amyloid beta 40-specific antibody induces amyloid beta sequestration. These results indicate that C-terminal antibodies may be useful in amyloid beta sequestration therapy...
  58. pmc No cross-sectional influence of APOE epsilon4 dose on clinical tests in Alzheimer's disease
    Rochelle E Tractenberg
    Department of Neurology, Georgetown University School of Medicine, Washington, DC, USA
    Neurobiol Aging 30:1327-8. 2009
    ..No significant influence of epsilon4 was detected. APOE's effect in AD may occur prior to clinical symptoms, or may simply be more subtle than these instruments can detect...
  59. ncbi request reprint Georgetown University School of Medicine
    Pamela A Saunders
    Acad Med 79:S45-50. 2004
  60. ncbi request reprint Anti-inflammatory therapy for Alzheimer's disease: implications of the prednisone trial
    P S Aisen
    Department of Neurology, Georgetown University Medical Center, Washington, DC 20007, USA
    Acta Neurol Scand Suppl 176:85-9. 2000
    ..The ADCS has initiated a trial to determine whether treatment with a non-selective non-steroidal anti-inflammatory drug or a selective cyclooxygenase-2 inhibitor is effective in slowing the rate of cognitive decline in AD...
  61. ncbi request reprint A simple method to rule out dementia with temporal orientation
    Rochelle E Tractenberg
    Department of Neurology, Georgetown University, Washington, DC, USA Departments of Biostatistics, Bioinformatics and Biomathematics and Psychiatry, Georgetown University School of Medicine, Washington, DC, USA
    Alzheimers Dement 3:28-32. 2007
    ..Prospective validation of the TTO is warranted...
  62. ncbi request reprint Inflammatory processes and Alzheimer's disease
    Sally Walsh
    Department of Neurology, Georgetown University Medical Center, Washington, DC 20057, USA
    Expert Rev Neurother 4:793-8. 2004
    ..It is concluded that such treatments should not be recommended, although additional investigation is warranted...
  63. doi request reprint Volumetric MRI vs clinical predictors of Alzheimer disease in mild cognitive impairment
    A S Fleisher
    Department of Neurosciences, University of California, San Diego, CA, USA
    Neurology 70:191-9. 2008
    ..To compare volumetric MRI of whole brain and medial temporal lobe structures to clinical measures for predicting progression from amnestic mild cognitive impairment (MCI) to Alzheimer disease (AD)...
  64. doi request reprint Longitudinal plasma amyloid beta as a biomarker of Alzheimer's disease
    Robert A Rissman
    Alzheimer s Disease Cooperative Study, Department of Neurosciences, UCSD School of Medicine, La Jolla, CA 92037 0624, USA
    J Neural Transm 119:843-50. 2012
    ..In this review, we discuss recent data on plasma β-amyloid (Aβ) and examine the issues that have arisen in establishing it as a reliable biomarker of AD...
  65. ncbi request reprint Benchmarking a test of temporal orientation with data from american and taiwanese persons with Alzheimer's disease and american normal elderly
    Rochelle E Tractenberg
    Department of Biomathematics and Biostatistics, Georgetown University School of Medicine, Washington, DC 20008, USA
    Neuroepidemiology 24:110-6. 2005
    ..TTO may be a useful component of cognitive screening efforts...
  66. doi request reprint An update on huperzine A as a treatment for Alzheimer's disease
    John T Little
    Georgetown University Hospital, Department of Psychiatry, 3800 Reservoir Road, NW, Kober Cogan 604, Washington, DC 20007, USA
    Expert Opin Investig Drugs 17:209-15. 2008
    ..This paper reviews the development of huperzine A as a treatment for AD, including the Phase II trial now under way in the US...
  67. ncbi request reprint A Phase II study targeting amyloid-beta with 3APS in mild-to-moderate Alzheimer disease
    P S Aisen
    Department of Neurology, Georgetown University Medical Center, Washington, DC, USA
    Neurology 67:1757-63. 2006
    ....
  68. pmc Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease
    Randall J Bateman
    Department of Neurology, Washington University School of Medicine, 660 S, Euclid, Campus Box 8111, St Louis, MO 63110, USA
    Alzheimers Res Ther 3:1. 2011
    ..Clinical trials in autosomal-dominant Alzheimer's disease may test the amyloid hypothesis, determine the timing of treatment, and lead the way to Alzheimer's disease prevention...
  69. pmc Recent developments in Alzheimer's disease therapeutics
    Michael S Rafii
    Department of Neurosciences, University of California San Diego, Gilman Drive M C 0949, La Jolla, CA 92093, USA
    BMC Med 7:7. 2009
    ..In this review, we briefly discuss the current status of Alzheimer's disease therapies under study, as well the scientific context in which they have been developed...
  70. pmc Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization
    R C Petersen
    Department of Neurology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Neurology 74:201-9. 2010
    ..Neuroimaging measures and chemical biomarkers may be important indices of clinical progression in normal aging and mild cognitive impairment (MCI) and need to be evaluated longitudinally...
  71. ncbi request reprint Cyclooxygenase (COX)-2 and cell cycle activity in a transgenic mouse model of Alzheimer's disease neuropathology
    Zhongmin Xiang
    Neuroinflammation Research Laboratories, Department of Psychiatry, Mount Sinai School of Medicine, One Gustave L Levy Place, New York, NY 10029, USA
    Neurobiol Aging 23:327-34. 2002
    ....
  72. ncbi request reprint NSAIDs and hypertension
    Paul S Aisen
    Arch Intern Med 163:1115; author reply 1115-6. 2003
  73. ncbi request reprint Pharmacologic treatment options in Alzheimer's disease: optimizing disease management
    Paul S Aisen
    J Am Acad Nurse Pract . 2005
    ..In addition, memantine and a ChEI appear to produce an additive effect resulting in a well-tolerated, effective treatment strategy...
  74. doi request reprint Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study
    Rachelle S Doody
    Alzheimer s Disease and Memory Disorders Center, Baylor College of Medicine, Houston, TX, USA
    Lancet 372:207-15. 2008
    ..More effective treatments are needed. We assessed the safety, tolerability, and efficacy of dimebon in the treatment of patients with mild-to-moderate Alzheimer's disease...
  75. doi request reprint Tarenflurbil: a shot on goal
    Paul S Aisen
    Lancet Neurol 7:468-9. 2008
  76. ncbi request reprint The inflammatory hypothesis of Alzheimer disease: dead or alive?
    Paul S Aisen
    Alzheimer Dis Assoc Disord 22:4-5. 2008
  77. ncbi request reprint Deglycosylated anti-amyloid beta antibodies reduce microglial phagocytosis and cytokine production while retaining the capacity to induce amyloid beta sequestration
    Kazuyuki Takata
    Department of Neurobiology, Kyoto Pharmaceutical University and 21st Century COE Program, Kyoto 607 8414, Japan
    Eur J Neurosci 26:2458-68. 2007
    ..We conclude that deglycosylated antibodies effectively induced Abeta sequestration without provoking neuroinflammation; thus, these deglycosylated antibodies may be optimal for sequestration therapy for Alzheimer's disease...
  78. ncbi request reprint ADCS Prevention Instrument Project: overview and initial results
    Steven H Ferris
    Alzheimer s Disease Center, New York University School of Medicine, New York, NY 10016, USA
    Alzheimer Dis Assoc Disord 20:S109-23. 2006
    ..Initial results for the experimental instruments and for the book club are reported in separate accompanying articles...
  79. ncbi request reprint BACE1 inhibition reduces endogenous Abeta and alters APP processing in wild-type mice
    Kouhei Nishitomi
    Pain and Neurology, Discovery Research Laboratories, Shionogi Co Ltd, Shiga, Japan
    J Neurochem 99:1555-63. 2006
    ..Studies using our new ELISA in non-transgenic mice provide more accurate evaluation of Abeta-reducing strategies than was previously feasible...
  80. ncbi request reprint NAP: research and development of a peptide derived from activity-dependent neuroprotective protein (ADNP)
    Illana Gozes
    Department of Human Molecular Genetics and Biochemistry, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 69978, Israel
    CNS Drug Rev 11:353-68. 2005
    ..NAP is poised for further clinical development targeting several indications, including Alzheimer's disease...
  81. ncbi request reprint Oral administration of pyridostigmine bromide and huperzine A protects human whole blood cholinesterases from ex vivo exposure to soman
    Richard K Gordon
    Walter Reed Army Institute of Research, Division of Biochemistry, 503 Robert Grant Rd, Silver Spring, MD 20910 7500, USA
    Chem Biol Interact 157:239-46. 2005
    ..The WRAIR WB ChE assay will fulfill the requirement for rapid and reliable monitoring of such exposure in military and civilian populations...
  82. ncbi request reprint An aspirin a day for Alzheimer's disease?
    Paul S Aisen
    Lancet Neurol 7:20-1. 2008
  83. ncbi request reprint Treatment for MCI: is the evidence sufficient?
    Paul S Aisen
    Neurology 70:2020-1. 2008
  84. ncbi request reprint Development of Abeta terminal end-specific antibodies and sensitive ELISA for Abeta variant
    Yuko Horikoshi
    Immuno biological Laboratories Co, Ltd, Fujioka shi, Gunma 375 0005, Japan
    Biochem Biophys Res Commun 319:733-7. 2004
    ..A combination of C-termini antibodies and an antibody against the middle region of Abeta detects mouse Abeta in non-transgenic mouse brains...